Pillar Clinical Research LLC is categorized under Outpatient Drug Clinics in Dallas, TX and active since 2008.
Pillar Clinical Research LLC was established in 2008, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Outpatient Drug Clinics business, which does work in the B2C market, and is classified as a Outpatient Drug Clinics, under code number 621498 by the NAICS.
If you are seeking more information, feel free to contact Brian E Craig at the company’s single location by writing to 11520 North Cntl Expressway # 126, Dallas, Texas TX 75243 or by phoning (214) 341-1953. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Pillar Clinical Research LLC |
| Contact Person: | Brian E Craig |
| Address: | 11520 North Cntl Expressway # 126, Dallas, Texas 75243 |
| Phone Number: | (214) 341-1953 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2008 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Outpatient Drug Clinics |
| SIC Code: | 8093 |
| NAICS Code: | 621498 |
| Share This Business: |
Pillar Clinical Research LLC was started in 2008 to provide professional Outpatient Drug Clinics under the SIC code 8093 and NAICS code 621498. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Brian E Craig for inquiries that concern Pillar Clinical Research LLC by calling the company number (214) 341-1953, as your correspondence is most welcome. Additionally, the physical location of the single location of Pillar Clinical Research LLC can be found at the coordinates 32.90675,-96.768369 as well as the street address 11520 North Cntl Expressway # 126 in Dallas, Texas 75243.
For its online presence, you may visit Pillar Clinical Research LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.